Grant of PDMR Options

RNS Number : 1423N

Instem plc

28 September 2021

 

Instem plc

("Instem", the "Company")

Grant of PDMR Options

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that Phil Reason (Chief Executive Officer) and Nigel Goldsmith (Chief Financial Officer) have each been granted awards of nil-cost options over 25,000 Ordinary Shares under the Instem plc 2018 Long Term Incentive Plan ("LTIP").  These options will ordinarily vest and become exercisable in 2024 pursuant to the rules of the LTIP and are subject to meeting share price targets.

After these grants of options, Mr Reason and Mr Goldsmith hold options over a total of 208,816 and 279,531 Ordinary Shares, respectively. 

For further information, please contact:

Instem plc	Via Walbrook
Phil Reason, CEO
Nigel Goldsmith, CFO
Singer Capital Markets (Nominated Adviser & Broker)	[phone]
Peter Steel, Alex Bond, Daniel Dearden-Williams (Corporate Finance)
Rachel Hayes (Corporate Broking)
Walbrook Financial PR	[phone]
Tom Cooper	[e-mail]
Nick Rome
Nicholas Johnson

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Phil Reason
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Instem plc
b)	LEI	213800PILYUFNNROQX68
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Grant of nil cost options under the Company's LTIP
	Identification code	GB00B3TQCK30
b)	Nature of the transaction	Grant of nil cost options under the Company's LTIP
c)	Price(s) and volume(s)
			Price	Volume(s)
			Nil	25,000
d)	Aggregated information
	- Aggregated volume	N/A - Single transaction
	- Price
e)	Date of the transaction	27 September 2021
f)	Place of the transaction	Off-market transaction

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Nigel Goldsmith
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Instem plc
b)	LEI	213800PILYUFNNROQX68
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of 10p each
	Identification code	GB00B3TQCK30
b)	Nature of the transaction	Grant of nil cost options under the Company's LTIP
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			Nil	25,000
d)	Aggregated information	N/A - Single Transaction
	- Aggregated volume
	- Price
e)	Date of the transaction	27 September 2021
f)	Place of the transaction	Off-market transaction

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.

To learn more about Instem solutions and its mission, please visit  www.instem.com

 

END

 

 

DSHDKOBQBBKBDCB